oversight, including business continuity risks, it is supported in this function by its audit committee, compensation committee, nominating and corporate governance committee, and science and
technology committee. Each of the committees regularly reports to the Board of Directors. Additionally, managements involvement in day-to-day risk management
enables our disclosure committee, which consists of members of management, to assist our Chief Executive Officer and Chief Financial Officer in the effective design, establishment, maintenance, review, and evaluation of the Companys disclosure
controls and procedures. The Companys management, led by our Chief Executive Officer and executive team, implements and supervises day-to-day risk management processes.
The audit committee assists the Board of Directors in fulfilling its risk oversight responsibilities by periodically reviewing our accounting,
reporting and financial practices, including the integrity of our financial statements, the surveillance of administrative and financial controls, our compliance with legal and regulatory requirements, and our enterprise risk management program.
Through its regular meetings with management, including the finance, legal, tax, compliance, and information technology functions, the audit committee reviews and discusses significant areas of our business and summarizes for the Board of Directors
areas of risk and the appropriate mitigating factors. The compensation committee assists the Board of Directors by overseeing and evaluating risks related to the Companys compensation structure and compensation programs, including the
formulation, administration and regulatory compliance with respect to compensation matters, and coordinating, along with the Chair of the Board of Directors, succession planning discussions. The nominating and corporate governance committee assists
the Board of Directors by overseeing and evaluating programs and risks associated with Board organization, membership and structure, and corporate governance. The science and technology committee assists the Board of Directors by overseeing and
evaluating programs and risks associated with research and development activities, including clinical trials sponsored by the Company. In addition, the Board of Directors receives periodic detailed operating performance reviews from management.
Committee Charters and Corporate Governance Guidelines
Our Corporate Governance Guidelines, charters of the audit committee, compensation committee, nominating and corporate governance committee,
and science and technology committee, and other corporate governance information are available in the Corporate Governance - Governance Documents section of the Investors & Media page of our website located at
www.evelobio.com, or by writing to our Secretary at our offices at 620 Memorial Drive, Cambridge, MA 02139.
Justice,
Equity, Diversity and Inclusion
We believe that creating a just, equitable, diverse, and inclusive culture is critical to attracting,
motivating and retaining the talent to deliver on our mission of providing affordable healthcare to people across the globe, and moreover an integral element of responsible corporate stewardship. Our nominating and corporate governance committee
engages with management on matters such as employee development, corporate culture and engagement, as well as justice, equality, diversity and inclusion, or JEDI, initiatives.
In 2021, we re-organized our existing efforts by creating our formal JEDI working group, which is
dedicated to advancing key JEDI initiatives and educating our broader employee base about JEDI subjects more generally. Our leadership team champions these efforts. Employees from across our business platform, including from senior management and
other leadership positions, comprise the active sitting members of our JEDI working group. Current JEDI initiatives include empowering our employee resource groups, conducting employee surveys regarding past and current experiences and backgrounds,
introducing new learning and development opportunities, strengthening our talent acquisition strategies, and formulating new approaches to further improve outreach to diverse candidate sources.
As of December 31, 2022, approximately 45% of our workforce was born outside of North America, and our employees came from over 15
countries around the world. As of the Record Date, our Board of Directors
47